HK1245133A1 - 用伊立替康脂質體治療乳腺癌 - Google Patents
用伊立替康脂質體治療乳腺癌Info
- Publication number
- HK1245133A1 HK1245133A1 HK18104815.5A HK18104815A HK1245133A1 HK 1245133 A1 HK1245133 A1 HK 1245133A1 HK 18104815 A HK18104815 A HK 18104815A HK 1245133 A1 HK1245133 A1 HK 1245133A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- treatment
- breast cancer
- liposomal irinotecan
- irinotecan
- liposomal
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
- A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Dispersion Chemistry (AREA)
- Dermatology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462089685P | 2014-12-09 | 2014-12-09 | |
PCT/US2015/064491 WO2016094402A1 (en) | 2014-12-09 | 2015-12-08 | Treatment of breast cancer with liposomal irinotecan |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1245133A1 true HK1245133A1 (zh) | 2018-08-24 |
Family
ID=54979964
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK18104815.5A HK1245133A1 (zh) | 2014-12-09 | 2018-04-12 | 用伊立替康脂質體治療乳腺癌 |
Country Status (6)
Country | Link |
---|---|
US (2) | US20160346272A1 (zh) |
EP (1) | EP3229802A1 (zh) |
JP (3) | JP7113619B2 (zh) |
AU (1) | AU2015360761B2 (zh) |
HK (1) | HK1245133A1 (zh) |
WO (1) | WO2016094402A1 (zh) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9717724B2 (en) | 2012-06-13 | 2017-08-01 | Ipsen Biopharm Ltd. | Methods for treating pancreatic cancer using combination therapies |
AU2013202947B2 (en) | 2012-06-13 | 2016-06-02 | Ipsen Biopharm Ltd. | Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan |
US11318131B2 (en) | 2015-05-18 | 2022-05-03 | Ipsen Biopharm Ltd. | Nanoliposomal irinotecan for use in treating small cell lung cancer |
WO2017031445A1 (en) | 2015-08-20 | 2017-02-23 | Merrimack Pharmaceuticals, Inc. | Combination therapy for cancer treatment |
CN108495629A (zh) * | 2015-08-21 | 2018-09-04 | 益普生生物制药有限公司 | 使用包含脂质体伊立替康和奥沙利铂的组合疗法治疗转移性胰腺癌的方法 |
EP3362049A1 (en) | 2015-10-16 | 2018-08-22 | Ipsen Biopharm Ltd. | Stabilizing camptothecin pharmaceutical compositions |
JP2019533684A (ja) | 2016-11-02 | 2019-11-21 | イプセン バイオファーム リミティド | リポソームイリノテカン、オキサリプラチン、5−フルオロウラシル(およびロイコボリン)を含む併用療法を用いる胃がんの処置 |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI283575B (en) * | 2000-10-31 | 2007-07-11 | Eisai Co Ltd | Medicinal compositions for concomitant use as anticancer agent |
WO2003030864A1 (en) * | 2001-05-29 | 2003-04-17 | Neopharm, Inc. | Liposomal formulation of irinotecan |
CN103948545B (zh) | 2004-05-03 | 2017-10-03 | 益普生生物制药公司 | 用于药物输送的脂质体 |
US8658203B2 (en) * | 2004-05-03 | 2014-02-25 | Merrimack Pharmaceuticals, Inc. | Liposomes useful for drug delivery to the brain |
AU2007227466B2 (en) * | 2006-03-16 | 2011-11-17 | Bionumerik Pharmaceuticals, Inc. | Anti-cancer activity augmentation compounds and formulations and methods of use thereof |
EP2595619A1 (en) * | 2010-07-19 | 2013-05-29 | BiPar Sciences, Inc. | Methods of treating metastatic breast cancer with 4-iodo-3-nitrobenzamide and irinotecan |
AU2013202947B2 (en) * | 2012-06-13 | 2016-06-02 | Ipsen Biopharm Ltd. | Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan |
US20140120157A1 (en) * | 2012-09-19 | 2014-05-01 | Georgetown University | Targeted liposomes |
WO2014113167A1 (en) * | 2012-12-14 | 2014-07-24 | Merrimack Pharmaceuticals, Inc. | Non-invasive imaging methods for patient selection for treatment with nanoparticulate therapeutic agents |
WO2017031445A1 (en) * | 2015-08-20 | 2017-02-23 | Merrimack Pharmaceuticals, Inc. | Combination therapy for cancer treatment |
CN108495629A (zh) * | 2015-08-21 | 2018-09-04 | 益普生生物制药有限公司 | 使用包含脂质体伊立替康和奥沙利铂的组合疗法治疗转移性胰腺癌的方法 |
EP3362049A1 (en) * | 2015-10-16 | 2018-08-22 | Ipsen Biopharm Ltd. | Stabilizing camptothecin pharmaceutical compositions |
-
2015
- 2015-12-08 WO PCT/US2015/064491 patent/WO2016094402A1/en active Application Filing
- 2015-12-08 EP EP15813999.8A patent/EP3229802A1/en not_active Withdrawn
- 2015-12-08 JP JP2017530656A patent/JP7113619B2/ja active Active
- 2015-12-08 AU AU2015360761A patent/AU2015360761B2/en active Active
- 2015-12-09 US US14/964,571 patent/US20160346272A1/en not_active Abandoned
-
2018
- 2018-04-12 HK HK18104815.5A patent/HK1245133A1/zh unknown
-
2019
- 2019-12-11 US US16/711,072 patent/US20200360367A1/en not_active Abandoned
-
2020
- 2020-02-13 JP JP2020022400A patent/JP2020073601A/ja not_active Withdrawn
-
2022
- 2022-03-22 JP JP2022045463A patent/JP2022079545A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
AU2015360761B2 (en) | 2021-05-20 |
US20160346272A1 (en) | 2016-12-01 |
EP3229802A1 (en) | 2017-10-18 |
JP2017537124A (ja) | 2017-12-14 |
JP2020073601A (ja) | 2020-05-14 |
AU2015360761A1 (en) | 2017-06-15 |
JP2022079545A (ja) | 2022-05-26 |
JP7113619B2 (ja) | 2022-08-05 |
WO2016094402A1 (en) | 2016-06-16 |
US20200360367A1 (en) | 2020-11-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL259783A (en) | Methods of treatment of malignant diseases | |
IL250677A0 (en) | Cancer treatment using anti-nkg2a agents | |
IL261959A (en) | Cancer treatment with tg02 | |
RS61536B1 (sr) | Kombinacije fgfr- i cmet-inhibitora za lečenje kancera | |
IL248487A0 (en) | Methods for treating early breast cancer with trastuzumab-dmi-mcc and pertuzumab | |
HK1245133A1 (zh) | 用伊立替康脂質體治療乳腺癌 | |
IL251761A0 (en) | Cancer treatment with immune system stimulants | |
IL263835A (en) | Exosome-guided treatment of cancer | |
IL247940A0 (en) | Treatment of cancer damaged by 1brca or resistant cancers | |
SG11201701076TA (en) | Diagnosis of cancer | |
GB201409363D0 (en) | Skin cancer treatment | |
GB201408297D0 (en) | Treatment of cancer | |
GB201403083D0 (en) | Treatment of cancer | |
IL252639A0 (en) | Breast cancer treatment using taxane | |
HK1232118A1 (zh) | 癌症的治療 | |
EP3389670A4 (en) | METHODS OF TREATING BREAST CANCER | |
EP3125878A4 (en) | Methods of treating breast cancer | |
GB201417456D0 (en) | Treatment of cancer | |
GB201407837D0 (en) | Methods of cancer therapy | |
GB201622214D0 (en) | treatment of cancer | |
GB201512723D0 (en) | Treatment of cancer | |
GB201417465D0 (en) | Treatment of cancers | |
GB201604621D0 (en) | Treatment of cancer | |
GB201604293D0 (en) | Treatment of cancer | |
GB201507928D0 (en) | Treatment of cancer |